Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06311721 · ClinicalTrials.gov registry record · Phase 3
A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer
A Phase 3 study of Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, sponsored by Amgen.
- Active
- Registry status
- Phase 3
- Development phase
- 315
- Enrollment target
- 20
- Study locations
NCT06311721: Active Phase 3 study of Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, sponsored by Amgen.
NCT06311721 is a Phase 3 study of Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer that is active but no longer recruiting, run by Amgen. The registered enrollment target is 315 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06311721, a Phase 3 study of Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 315 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
Conditions Studied
Interventions
- DRUG ABP 234
- DRUG Pembrolizumab (US)
- DRUG Pembrolizumab (EU)
Study Locations (20)
California
- Precision NextGen Oncology and Research Center - Beverly Hills
- TOI Clinical Research - Cerritos
- Cancer and Blood Specialty Clinic (CBSC) - Los Alamitos
- Valkyrie Clinical Trials - Los Angeles
- PIH Health Hospital - Whittier
Florida
- Millennium Oncology - Hollywood - Hollywood
- BRCR Medical Center Inc. - Tamarac
Texas
- Millennium Research and Clinical Development, LLC - Houston
- Texas Oncology, P.A - San Antonio
Buenos Aires
- Instituto de Investigaciones Clinicas Mar del Plata - Mar del Plata
- Centro de Investigacion Pergamino SA - Pergamino
Santa Fe Province
- Sanatorio Britanico De Rosario - Rosario
- Hospital Provincial del Centenario - Rosario
Illinois
- Accellacare Duly - Plainfield
Iowa
- Accellacare of McFarland - Ames
Michigan
- Detroit Clinical Research Center, PC - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 315 participants |
| Start Date | 2024-09-09 |
| Est. Completion | 2028-05-29 |
| Phase | Phase 3 |
What the registry record for NCT06311721 still lists
NCT06311721 is an interventional study that assigns participants to a tested intervention. The registered 315 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (59% lower).
The record links to 1 condition, with Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which ABP 234 is the first listed.
NCT06311721 names 20 study sites across 12 states, led by California, Florida, Texas.
Frequently Asked Questions
What is clinical trial NCT06311721 about?
NCT06311721 is a clinical study titled "A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer". The primary objective of this study is to compare the efficacy of ABP 234 with the pembrolizumab reference product (Keytruda®).
What is the current status of trial NCT06311721?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 315 participants. The study started on 2024-09-09. Estimated completion is 2028-05-29.
What conditions does trial NCT06311721 study?
This clinical trial studies the following conditions: Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06311721?
The interventions under investigation include: ABP 234 (DRUG), Pembrolizumab (US) (DRUG), Pembrolizumab (EU) (DRUG).
Who is sponsoring clinical trial NCT06311721?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06311721 being conducted?
This trial has 20 study locations across California, Florida, Illinois, Iowa, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06311721's enrollment target sits among peer trials
315 1093rd of 2000 higher than 905 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04812366 · 315 participants · Phase 2
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
- NCT05101460 · 315 participants
An All Comers Registry For Normothermic Ex Vivo Lung Perfusion (EVLP) as Assessment of Donor Lungs for Transplant
- NCT05897320 · 315 participants · Phase 3
A Study of Eptinezumab in Pediatric Participants With Episodic Migraine
- NCT06439082 · 315 participants · Phase 3
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI